Last updated: March 9, 2026
What is the Drug Associated with NDC 65862-0457?
NDC 65862-0457 corresponds to Firdapse (amifampridine), marketed by Catalyst Pharmaceuticals. Approved by the FDA in 2018, Firdapse treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting neuromuscular transmission.
Market Size and Patient Population
- The prevalence of LEMS is approximately 3.4 per million population, with an estimated 1,000-2,000 diagnosed patients in the U.S.
- The majority of patients are diagnosed in adults aged 40-60.
- No direct competitor with FDA approval exists; off-label use of 3,4-diaminopyridine (3,4-DAP) compounds occurs but lacks formal approval.
Current Market Dynamics
Regulatory and Reimbursement Landscape
- Firdapse received FDA approval in 2018, expanding access for LEMS patients.
- Medicare and private insurers reimburse Firdapse; pricing and coverage impacts access.
- The high cost influences uptake, especially in the absence of generic competition.
Pricing Context
- Firdapse's wholesale acquisition cost (WAC) as of 2023 approximates $375 per 10 mg tablet.
- The average monthly cost ranges between $15,000 and $18,000 depending on dosing, which typically involves 10-20 mg three times daily.
Competition and Market Entry
- As of 2023, no FDA-approved biosimilar or generic versions are commercially available.
- Off-label 3,4-DAP use is limited due to regulatory status.
- Catalyst maintains exclusivity through patent protections; new entrants face patent barriers expected to last until at least 2030.
Price Projections: Near and Mid-Term Outlook
| Scenario |
Price Range per 10 mg Tablet |
Key Factors |
| Status Quo (2023-2025) |
$375 - $400 |
Patent protection, limited competition, high disease rarity |
| Potential Biosimilar Entry (2025-2030) |
$250 - $300 |
Patent expiry, regulatory approvals |
| Market Expansion (Post-2030) |
$150 - $250 |
Increased competition, generic availability, volume growth |
Analysis:
- Short-term (next 2 years): The pricing remains near current levels due to patent exclusivity and limited competition. Slight upward pressure may occur if manufacturing costs increase or demand rises.
- Mid-term (2025-2030): As patents expire or licensing deals are executed, biosimilar products could enter the market, reducing prices by approximately 20-30%.
- Long-term (post-2030): Price reductions could reach 40-60% compared to current levels as generics or biosimilars achieve market share.
Factors Influencing Price Trends
- Patent expirations and legal challenges.
- Regulatory pathways for biosimilar approval.
- Market penetration of biosimilars or generics.
- Healthcare policy shifts emphasizing cost containment.
- Clinical guidelines evolving to favor or restrict certain treatments.
Investment and R&D Impact
- Pharmaceutical companies investing in biosimilar development could accelerate price declines.
- Catalyst Pharmaceuticals might pursue patent extensions or new formulations to extend exclusivity.
- R&D focusing on alternative delivery methods or combination therapies may impact future pricing strategies.
Key Takeaways
- NDC 65862-0457 (Firdapse) markets a rare disease treatment with high current pricing due to exclusivity.
- Market size remains small, limiting overall revenue but maintaining high per-patient margins.
- Price trajectories depend heavily on patent status; competition is unlikely before 2025.
- Long-term reductions expected post-patent expiry, proportional to the pace of biosimilar or generic adoption.
- Regulatory, legal, and policy developments could significantly influence future pricing.
FAQs
1. How long is the patent protection for Firdapse?
Patent protections are expected to last until at least 2030, considering current patents and anticipated extensions.
2. What are the main competitors for Firdapse?
No direct FDA-approved competitors currently exist. Off-label use of 3,4-DAP compounds is common but less regulated.
3. Will Firdapse’s price decrease significantly in the next 5 years?
Likely, if biosimilars or generics are approved and market entry occurs after patent expiration, typically around 2025-2030.
4. How does the rarity of LEMS influence pricing?
The small patient population justifies high per-unit prices but limits overall revenue potential for expanding the market.
5. Are there any recent or upcoming regulatory changes impacting pricing?
No major regulatory shifts are anticipated soon. Future biosimilar approvals and policy reforms could modify the pricing landscape.
References
- Catalyst Pharmaceuticals. (2023). Firdapse prescribing information.
- FDA. (2018). Firdapse (amifampridine) approval announcement.
- MarketScope. (2023). Rare disease drug market analysis.
- IQVIA. (2023). U.S. drug pricing and reimbursement report.
- National Organization for Rare Disorders. (2022). Lambert-Eaton myasthenic syndrome facts.
